Compare VanEck Video Gaming and eSports ETF (ESPO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs Summit Therapeutics Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $91.98, while Summit Therapeutics Inc trades at $13.77 (market cap $11.70B). The key difference: VanEck Video Gaming and eSports ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ESPO | SMMT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $29.32 |
52-Week Low | $85.25 | $13.05 |
Market Cap | — | $11.70B |
Enterprise Value | — | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $91.98, up 0.47% today, with technical indicators showing a bullish trend supported by moving averages. The ETF benefits from positive sentiment around AI-driven profit potential in the gaming industry. Recent institutional buying by Assetmark Inc. highlights growing confidence in the digital entertainment sector's growth prospects.
The outlook remains positive given AI's potential to boost gaming industry profits by $22 billion, though risks include sector competition and market volatility. Current technical strength near key support levels suggests potential for continued upward momentum if broader market conditions remain favorable.
Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.
Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
